Literature DB >> 17194513

Health effects classification and its role in the derivation of minimal risk levels: immunological effects.

H G Abadin1, C-H S J Chou, F T Llados.   

Abstract

The Agency for Toxic Substances and Disease Registry (ATSDR) derives health-based guidance values known as minimal risk levels (MRLs). By definition, an MRL is a substance-specific estimate of the daily human exposure to a substance that is likely to be without an appreciable risk of adverse, noncancer effects over a specified duration of exposure. MRLs are preferentially derived from human studies, if available, or from the most sensitive animal species and the endpoint that is most relevant for humans. To date, the agency has derived 346 MRLs. Fifteen MRLs were derived for 11 different chemicals where the database has identified the immune system as the most sensitive target of toxicity. The chemicals include benzene, chlorfenvinphos, endosulfan, heptachlor, gamma-hexachlorocyclohexane, dibutyl tin, tributyl tin, PCBs, 2,3,4,7,8-pentachlorodibenzofuran, 2,3,7,8-tetrachlorodibenzo-p-dioxin, and 2,4-dichlorophenol. The agency's rationale for classification of immunological endpoints is discussed and a brief description given of the critical studies selected for MRL development using immune system endpoints.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17194513     DOI: 10.1016/j.yrtph.2006.11.001

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  2 in total

1.  A simple procedure for estimating pseudo risk ratios from exposure to non-carcinogenic chemical mixtures.

Authors:  Franco Scinicariello; Christopher Portier
Journal:  Arch Toxicol       Date:  2015-02-11       Impact factor: 5.153

2.  The human exposome and health in the Anthropocene.

Authors:  Oskar Karlsson; Joacim Rocklöv; Alizée P Lehoux; Jonas Bergquist; Anna Rutgersson; Martin J Blunt; Linda S Birnbaum
Journal:  Int J Epidemiol       Date:  2021-05-17       Impact factor: 7.196

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.